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Abstract 
Aim:  To prepare RGD-modified long circulating liposome (LCL) loading matrine 
(RGD-M-LCL) to improve the tumor-targeting and efficacy of matrine. Methods: LCL which 
was prepared with HSPC, cholesterol, DSPE-PEG2000 and DSPE-PEG-MAL was modified 
with an RGD motif confirmed by high performance liquid chromatography (HPLC). The 
encapsulation efficiency of RGD-M-LCL was also detected by HPLC. MTT assay was used to 
examine the effects of RGD-M-LCL on the proliferation of Bcap-37, HT-29 and A375 cells. 
The percentage of apoptotic cells and morphological changes in Bcap-37 cells treated with 
RGD-M-LCL were detected by Annexin-V-FITC/PI affinity assay and observed under light 
microscope, respectively. Results: Spherical or oval single-chamber particles of uniform sizes 
with little agglutination or adhesion were observed under transmission electronic micro-
scope. The RGD motif was successfully coupled to the DSPE-PEG-MAL on liposomes, as 
confirmed by HPLC. An encapsulation efficiency of 83.13% was obtained when the drug-lipid 
molar ratio was 0.1, and the encapsulation efficiency was negatively related to the drug-lipid 
ratio in the range of 0.1~0.4, and to the duration of storage. We found that, compared with 
free matrine, RGD-M-LCL had much stronger in vitro activity, leading to anti-proliferative and 
pro-apoptotic effects against cancer cells (P<0.01). Conclusion: RGD-M-LCL, a novel deli-
very system for anti-cancer drugs, was successfully prepared, and we demonstrated that the 
use of this material could augment the effects of matrine on cancer cells in vitro. 
Key words: Matrine, Liposomes, Cyclic arginine- glycine-aspartic acid, Drug delivery systems. 
Introduction 
Matrine, the major active component of the tra-
ditional Chinese medicine Sophora flavescens, has been 
used to treat jaundice, reduce liver enzyme activity, 
and prevent hepatic fibrosis (1,2). In recent years, 
studies have indicated that matrine also inhibits tu-
mor cell proliferation (3), and induces cellular diffe-
rentiation (4) and apoptosis (5). Our previous study 
showed that matrine could inhibit proliferation and 
induce apoptosis in human malignant melanoma 
A375 cells in a dose-dependent manner. Furthermore, 
it effectively suppressed their adhesion and inva-
siveness in vitro (6). However, like most low molecu-
lar weight drugs, matrine is able to freely traverse in 
and out of blood vessels to distribute to non-tumor 
tissues, resulting in accumulation in the liver, spleen 
or kidneys, diminishing its effects on cancer cells. In 
addition, consistent with the results of other research 
groups, our previous study also showed that matrine Int. J. Med. Sci. 2010, 7 
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had fewer side-effects and broader indications com-
pared with conventional anti-cancer drugs. However, 
its anti-tumor activity was moderate, and its half 
maximal inhibitory concentration (IC50) was about 
2.01mM (6).  
In order to improve the tumor-specificity and 
efficacy of anti-tumor drugs, liposomes have been 
used extensively as delivery systems in both 
pre-clinical and clinical applications. Liposomes allow 
for enhanced drug delivery into tumors, and improve 
the accumulation of drugs in tumors via the enhanced 
permeability and retention (EPR) mechanism (7). 
However, the use of conventional vesicles cannot 
fully overcome their binding with serum components 
and uptake by mononuclear phagocyte system (MPS). 
To overcome such problems, long circulating lipo-
somes, modified with a hydrophilic or a glycolipid 
such as poly (ethylene glycol) (PEG) or monosialogan-
glioside (GM1), have been developed in the past sev-
eral years. The presence of PEG on the surface of the 
liposomal carrier has been  shown to extend 
blood-circulation time while reducing MPS uptake (8). 
Furthermore, several novel types of liposomes, such 
as ligand- or antibody-mediated liposomes  (9,10), 
have been developed to further enhance their tu-
mor-specificity and therapeutic efficacy. The use of 
these specific “vector” molecules showing affinity 
toward certain receptors or antigens highly expressed 
on the surface of the target tumor cells enhances their 
uptake and activity. Among the most commonly tar-
geted are the integrin receptors, including α5ß1, αγß3 
or α4ß1, which are highly expressed on breast, colon 
and rectal cancer, and melanoma cells (11-13). There-
fore, the arginine-glycine-aspartic acid (RGD) peptide, 
which is a ligand of several integrin receptors, has 
been used to modify oncolytic viral vectors, delivery 
vehicles, and the resulting molecules have been used 
as probes and radiotracers for tumor imaging (14-18). 
However, linear RGD-peptides are susceptible to 
chemical degradation, so the peptides were cyclized 
to confer rigidity and increase stability (19).  
In this study, we prepared liposomes loaded 
with matrine using hydrogenated soybean phospha-
tidylcholine (HSPC), cholesterol, 1,2- distea-
royl-sn-glycero-3-phosphoethanolamine 
-N-[PEG(2000)] (DSPE-PEG2000) and malei-
mide-[poly (ethylene glycol)]-1,2-dioleoyl-sn 
-glycero-3-phosphoethanolamine (DSPE-PEG-MAL), 
and modified them with RGD. The novel therapeutic 
approach was then evaluated by in vitro testing in 
human cancer cell lines. We observed that 
RGD-M-LCL had increased anti-proliferative activity 
and increased the induction of apoptosis in cancer 
cells compared to free matrine, supporting the further 
development of this novel delivery system for cancer 
therapy.  
Materials and Methods 
Preparation of RGD-modified long circulating 
liposome (LCL) loading matrine (RGD-M-LCL)  
L i p i d s  c o m p o s e d  o f  H S P C  ( L i p o i d ,  G e r m a n y ) ,  
cholesterol (Lipoid, Germany), DSPE-mPEG2000 
(Avanti, USA) and DSPE-PEG-MAL (Avanti, USA) in 
a molar ratio of 2:1:0.1:0.01, were dissolved in chloro-
form:methanol (9:1 vol/ vol) in a round-bottom flask. 
The solvent was evaporated to form a lipid film under 
reduced pressure and constant rotation (Rotovapor 
R-200, Buchi, Switzerland) at 40°C. The lipid film was 
hydrated with 300mmol/L citric acid (pH 4.0) at 62°C 
for 1 h, and in a magnetic stirrer for another 1 h, fol-
lowed by ultrasonication in an ice bath for 15 min. 
Then the sample of LCL was delivered to the Zhejiang 
California International NanoSystems Institute, and 
was processed by a microfluidizer (Microfluidics, 
USA). After microfluidizing, the LCL suspension was 
stored at 4°C until use.  
The Cyclic-RGD peptide (Arg-Gly-Asp- 
D-Phe-Cys, purity assayed by HPLC to be >98%) was 
synthesized by the Chinese Peptide Company 
(Hangzhou, China) and dissolved in 50 mM HEPES 
buffer (pH 6.5) at 1mg/mL, then the peptide was 
reacted with the LCL suspension with maleimide 
functional groups in a molar ratio of 1:10 
(RGD:maleimide) at room temperature overnight to 
prepare RGD-LCL. In this step, the sulfhydryl (-SH) 
group of cystine in the Cyclic-RGD couples to the 
maleimide groups at the distal end of 
DSPE-PEG-MAL on the liposomes (Figure 1) (20). 
Then, referring to the pH-gradient method (21), ma-
trine (purity determined to be >99% by HPLC, Nanj-
ing Tcm Institute Of Chinese Materia Medica, China) 
was added to the RGD-LCL in a drug-lipid ratio of 
0.1, 0.2 or 0.4, respectively, and mixed with NaH2PO4 
(pH 7.0) to obtain a desired pH gradient (inside pH 
4.0, outside pH7.0). Subsequently, the mixture was 
incubated under argon at 60°C for 30 min, and then 
the generation of RGD-modified long circulating li-
posome loading matrine (RGD-M-LCL) was com-
plete. Some RGD-M-LCL in a drug-lipid ratio of 0.1 
was stored at 4°C to determine its stability, particle 
size and the efficiency of drug-loading.  
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Figure 1. Schematic representation of the coupling reaction between the maleimide group on the distal end of the PEG 
chain on the LCL and the -SH group in the cyclic RGD peptide (19).  
 
 
 
HPLC analysis of the coupling of RGD to LCL  
Free Cyclo-RGD (250μg/mL or 15μg/mL) and 
conjunctive RGD-LCL equivalent to 15μg/mL RGD 
were analyzed by HPLC to ascertain the status of 
RGD. A Hypersil-BDS-C18-column (4.0 × 250 mm, 
Thermo, USA) was used with a mobile phase con-
sisting of 0.05% trifluoroacetic acid in water (eluant A) 
and 0.05% trifluoroacetic acid in acetonitrile (eluant 
B). The eluant gradient was set from 10% to 60% B in 
50 min, and subsequently back to 10% B over 5 min 
(19). The detection wavelength was 214nm, the flow 
rate was 1mL/min, and the injection volume was 
20μL. 
Lyophilization of RGD-M-LCL and measurement 
of its particle size 
RGD-M-LCL was freeze-dried by a cryoprotec-
tant of sugar in a sugar-lipid quality ratio of 2.0 (22), 
then was redissolved with DMEM. The size of the 
liposomes was measured before and after 
freeze-drying by a Zetasizer Nano (Malvern, United 
Kingdom). In addition, the samples were delivered to 
the Electronic Microscope Centre of Huajiachi Cam-
pus, Zhejiang University. Subsequently, liposomes 
were dyed with 3% phosphotungstic acid for negative 
staining, and then deposited to a copper screen for 
observation under transmission electronic microscope 
(Tecnai-co, Philip, the Netherlands) to evaluate their 
shape. 
Encapsulation efficiency and loading-drug stabil-
ity of the RGD-M-LCL. 
Matrine solutions at different concentrations 
(1.95 μg/mL, 3.91 μg/mL, 7.81 μg/mL, 15.63 μg/mL, 
31.25  μg/mL, 62.5 μg/mL, 125 μg/mL and 250 
μg/mL) were prepared. A Hypersil-BDS-C18-column 
was used with a mobile phase consisting of acetoni-
trile-alcohol-0.2%  triethylamine (8:2:90, pH adjusted 
to 3.0 with phosphoric acid), the detection wavelength 
was 210nm, the flow rate was 1mL/min and the in-
jection volume was 20μL. The unloaded matrine from 
different RGD-M-LCL samples obtained immediately 
after encapsulation, one or two weeks after encapsu-
lation, or following re-dissolution after freeze-drying, 
was separated by mini-gel columns of Sephadex-G50 
prepared in advance. In brief, incubation mixtures of 
200μL containing unloaded matrine and RGD-M-LCL 
were added onto mini-gel columns. Then particles of 
RGD-M-LCL were collected by centrifugation at 
2000rpm/min for 3min, while the free matrine was 
still isolated in the columns because of their differ-
ences in the sizes of the molecules. The amount of 
matrine collected from the RGD-M-LCL samples was 
determined by HPLC assay under the same condi-
tions. At the same time, total matrine present in each 
group before separation was also measured by HPLC. 
The encapsulation efficiency was calculated as Effi-
ciency = Matrine separated from liposomes (encap-
sulated)/matrine in unseparated liposomes (total) 
×100%. 
Cell culture  
The A375 melanoma cell line was purchased 
from the Shanghai Institute of Cell Biology, Chinese 
Academy of Sciences (Shanghai, China). The breast 
cancer Bcap-37 and colon cancer HT-29 cell lines were 
maintained in our lab. A375 cells and Bcap-37 cells 
were grown in RPMI1640 medium (GIBCO, USA) 
containing 10% heat-inactivated fetal bovine serum 
(Nuoding, China), and the HT-29 cells were grown in 
DMEM medium (GIBCO, USA) also containing 10% 
heat-inactivated fetal bovine serum. All of the cells 
were incubated at 37°C in a humidified atmosphere Int. J. Med. Sci. 2010, 7 
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with 50 mL/L CO2. RGD-M-LCL and RGD-LCL were 
r e - d i s s o l v e d  w i t h  D M E M  o r  R P M I 1 6 4 0  a f t e r  
freeze-drying. 
Effects of RGD-M-LCL on cell viability using 
MTT) assay 
Briefly, cells (5×103  per well) were seeded in 
96-well plates (Corning, USA). After subculturing 
them for 24 h, the cells were treated with matrine of 
different concentrations (0.0625 mg/mL, 0.125 
mg/mL, 0.25 mg/mL, 0.5 mg/mL) or RGD-M-LCL 
with matrine of equivalent concentrations. The con-
trol group consisted of cells in culture medium only. 
Experiments were carried out in triplicate. In order to 
observe the toxicity of RGD-LCL without matrine on 
cells, Bcap-37 cells were also treated with RGD-LCL of 
different concentrations (0.3125 mg/mL, 0.625 
mg/mL, 1.25 mg/mL, and 2.5 mg/mL), and 
RGD-M-LCL of different concentrations equivalent to 
these RGD-LCL concentrations. After exposure for 
48h, 100 μL of MTT (1 mg/mL) (Sigma-Aldrich, USA) 
was added to each well and the plates were incubated 
for an additional 4 h at 37°C. The MTT solution was 
removed by aspiration, and 150 μL of dimethylsul-
foxide (DMSO) (Sigma-Aldrich) was added to each 
well. Finally, the absorbance of each well was meas-
ured at 570 nm. All MTT assays were repeated two 
times. The relative growth rate was calculated as A570 
(test)/A570 (control). We assumed that the average 
A570 values of the control group were equal to 1, and 
then generated a histogram of cellular viability ac-
cording to the relative growth rate following the dif-
ferent treatments.  
Morphological observation  
Bcap-37 cells were seeded in 96-well plates for 24 
h before treatments as follows: matrine at 0.03215 
mg/mL or 0.0625 mg/mL, RGD-LCL at 0.625 mg/mL 
or 1.25 mg/mL, or RGD-M-LCL equivalent to the 
same concentrations of matrine and RGD-LCL. After 
being exposed to the different treatments for 48h, the 
Bcap-37 cells were observed under inverted light mi-
croscope (Olympus, Tokyo, Japan).  
Effect of RGD-M-LCL on cellular apoptosis  
The Annexin-V–fluorescein isothiocya-
nate/propidium iodide (Annexin-V-FITC/PI) double 
staining assay was used to detect cellular apoptosis. 
Bcap-37 cells were equally distributed into culture 
flasks, and treated with either culture medium only, 
matrine at 0.03215 mg/mL, RGD-LCL at 0.625 
mg/mL, or RGD-M-LCL equivalent to these concen-
trations of matrine and RGD-LCL. After 24 h of 
treatment, the cells were collected, washed with cold 
phosphate-buffered saline (PBS), and resuspended at 
2 × 106 cells /mL in Annexin-V binding buffer. The 
supernatant (100 μL/tube) was incubated with 5 μL of 
Annexin-V-FITC (Invitrogen, USA) and 5 μL of PI 
(Invitrogen, USA) for 15 min at room temperature in 
dark. Binding buffer (400 μL) was then added to each 
tube, followed by cytometric analysis (Coulter-XL, 
USA) within 1 h of staining. All experiments were 
repeated three times. 
Statistical analysis 
The SAS statistical software was used for statis-
tical analyses. The results are expressed as the means 
± standard deviations, and samples were subjected to 
multiple analysis of variance. The Dunnett-t test was 
performed to compare the mean between each test 
group and control group, and the SNK-q test was 
performed to compare the means between either two 
test groups. P < 0.05 was considered to be statistically 
significant. 
Results 
The RGD motif was successfully coupled to 
DSPE-PEG-MAL on liposomes  
HPLC analysis showed that free RGD at con-
centrations of 250 μg/mL or 15 μg/mL eluted with a 
retention time of ~20 minutes, and the peak area was 
dose-dependent. However, when RGD was conju-
gated to liposomes at the same concentration (15 
μg/mL) following the coupling step, there was no 
significant peak for the free RGD around 20 minutes 
(Figure 2), indicating successful coupling of the RGD 
to the surface of the liposomes. 
Assay of particle sizes and morphological ob-
servation of RGD-M-LCL 
The average size of liposomes processed by the 
microfluidizer was 97.59±1.93nm, with the liposomes 
appearing as a light milky-white and translucent 
suspension. Liposomes were found to be spherical or 
oval single-chamber particles of uniform sizes with 
little agglutination or adhesion under transmission 
electronic microscope. They showed little change in 
appearance or size when stored for one week, two 
weeks or four weeks at 4°C. However, the average 
size of liposomes re-dissolved after freeze-drying in-
creased to 295.77±5.52nm, and presented as larger 
particles with some agglutination under transmis-
sion electronic microscope (Figure 3-4, Table 1).  
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Figure 2. HPLC confirmation of RGD coupling to the liposomes. (A) Free RGD at 250 μg/mL eluted with a re-
tention time of ~20 minutes; (B) Free RGD at 15 μg/mL also eluted with a retention time of ~20 minutes, and the peak areas 
of the peaks in A and B demonstrate dose-dependence; (C) The liposome sample modified with the same concentration of 
15 μg/mL RGD following the coupling step showed no significant peak for the free RGD around 20 minutes. Int. J. Med. Sci. 2010, 7 
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Figure 3. Particle size of liposomes. The size of the liposomes was measured with a Zetasizer Nano using a dynamic 
light scattering technique. (A) The average size of liposomes immediately after encapsulation was 95.37nm, and the dis-
tribution width was 27.24nm; (B) The average size of liposomes following re-dissolution after freeze-drying was 301.9nm, 
and the distribution width was 165.8nm. 
 
   
Fig. 4 The ultrastructural morphology and size of liposomes observed under electron microscope (×3700). 
(A) After microfluidizing, the liposomes presented as spherical or oval single-chamber particles of uniform sizes with 
little agglutination or adhesion. (B) After the liposomes were re-dissolved following freeze-drying, they presented with 
increased size and some agglutination.  
 
Encapsulation efficiency and loading-drug stabil-
ity of RGD-M-LCL 
The peak areas for matrine in the concentration 
range from 1.95-250 μg/mL was linear in the HPLC 
assay, and the linear regression equation was 
Y=28.715X+33.322, with a correlation coefficient of 
0.9997. As shown in Table 1, the encapsulation effi-
ciency decreased with the increase in drug-lipid ratio, 
indicating that there was a significant effect of the 
drug-lipid ratio on the encapsulation efficiency. Dur-
ing the process of preservation of liposomes, the en-
capsulation efficiency also decreased due to the re-
lease of water-soluble drugs. Although the size of 
liposomes after freeze-drying increased, their encap-
sulation efficiency was still maintained at a high level.  Int. J. Med. Sci. 2010, 7 
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Table 1. Influence of the drug-lipid ratio and storage on the encapsulation efficiency and size of liposomes. 
 
* Compared with the group analyzed immediately after encapsulation, P<0.01; †compared with the group re-dissolved after freeze-drying, 
P<0.01. 
 
 
 
RGD-M-LCL augments the anti-proliferative and 
pro-apoptotic effects of matrine in cancer cells 
RGD-M-LCL significantly inhibited the growth 
of Bcap-37, HT-29 and A375 cells, compared with cells 
treated with the free matrine (P<0.01). Furthermore, 
the effects of the RGDF-M-LCL were dose-dependent 
(Figure 5). When Bcap-37 cells were used to assess the 
toxicity of RGD-LCL, we observed cytotoxicity of li-
posomes beginning at the 1.25 mg/mL or 2.5 mg/mL 
concentrations. Indicating that the liposomes them-
selves have some cytotoxic activity, we did not ob-
serve any significant differences between RGD-LCL 
and the equivalent RGD-M-LCL group at 2.5 mg/mL. 
However, in the 0.3125 mg/mL or 0.625 mg/mL 
groups that had low concentrations of RGD-LCL, 
there were no significant inhibitory effects induced by 
the liposomes on Bcap-37 cells. In contrast, the 
RGD-M-LCL equivalent to 0.3125 mg/mL or 
0.625mg/mL RGD-LCL significantly inhibited the 
growth of the cancer cells (P<0.01, Figure 6). We ob-
served under an inverted light microscope that, 
compared with free matrine and RGD-LCL, there was 
more pyknosis and a greater cell-free zone in cells 
treated with RGD-M-LCL of equivalent concentra-
tions (Figure 7).  
The flow cytometric results demonstrated that, 
compared with the control group, treatment with 
matrine alone at 0.03125 mg/mL had no effect on 
apoptosis in the cultured cancer cells (P>0.05) (Figure 
8). However, the percentage of apoptotic cells in cul-
tures treated with 0.625mg/mL RGD-LCL was in-
creased in comparison with the control group 
(12.25±2.33% vs 0.90±0.51%, P<0.05). Furthermore, the 
percentage of apoptotic cells in the RGD-M-LCL 
group was 35.40±2.68%, which was significantly 
higher than that in the control, 0.03125 mg/mL ma-
trine and 0.625 mg/mL RGD-LCL groups (P<0.05), 
indicating that the combination of RGD-LCL and ma-
trine leads to enhanced cytotoxic effects. 
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Figure 5. RGD-M-LCL led to a significant increase in the inhibition of cancer cell growth in a 
dose-dependent manner. Three cell lines, Bcap-37, HT-29 and A375, were treated with various concentrations of 
matrine and RGD-M-LCL equivalent to the same concentrations of matrine for 48h, and the A570 values following incu-
bation with MTT were measured by an enzyme-labeling analyzer. Data were compared to the control group (assumed to be 
1.0), and the relative viability of each experimental group was plotted. *P < 0.01 when compared with the equivalent matrine 
group.  
 
 
Figure 6. Comparison of the growth inhibitory effects of RGD-M-LCL and RGD-LCL on Bcap-37 cells. 
Bcap-37 cells were treated with various concentrations of RGD-LCL and RGD-M-LCL (equivalent to the same concen-
tration of RGD-LCL) for 48h, and were again plotted as the ratio to the control group. In the cells treated with 0.3125 
mg/mL or 0.625 mg/mL of RGD-LCL, the inhibitory effect of liposomes on Bcap-37 cells was minimal, while the RGD-M-LCL 
equivalent to the same dose of RGD-LCL strongly inhibited the growth of the cancer cells. However, in the cells treated 
with 1.25 mg/mL or 2.5 mg/mL of RGD-LCL, RGD-LCL itself was moderately cytotoxic to the Bcap-37 cells. *P < 0.01 when 
compared to the equivalent RGD-LCL group. Int. J. Med. Sci. 2010, 7 
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Figure 7. Morphological observation of Bcap-37 cells in different treatment groups. Bcap-37 cells were treated 
with different concentrations of free matrine, RGD-LCL or RGD-M-LCL for 48 h and observed with an inverted light 
microscope at low power (10 × 10). Compared with free matrine or RGD-LCL groups, there was more pyknosis and a 
larger cell-free zone in the cells treated with the equivalent RGD-M-LCL. (A) matrine (0.03125 mg/mL), (B) RGD-LCL 
(0.625 mg/mL), (C) RGD-M-LCL (equivalent to matrine of 0.03125 mg/mL and RGD-LCL of 0.625 mg/mL), (D) matrine 
(0.0625 mg/mL), (E) RGD-LCL (1.25 mg/mL), and (F) RGD-M-LCL (equivalent to matrine of 0.0625 mg/mL and RGD-LCL of 
1.25 mg/mL). 
 
Figure 8. Representative 
results of apoptosis in 
Bcap-37 cells in different 
treatment groups. Bcap-37 
cells were treated with different 
treatment of culture medium, 
free matrine, RGD-LCL or 
RGD-M-LCL for 24 h, then 
were stained with Annex-
in-V-FITC and PI, and assayed 
by flow cytometry. Compared 
with the control group, matrine 
at 0.03125 mg/mL had no effect 
on the apoptosis of cancer cells. 
However, RGD-LCL at 0.625 
mg/mL could induce apoptosis 
in the Bcap-37 cells. Further-
more, treatment with 
RGD-M-LCL led to apoptosis in 
37.1% of the cells, which was, 
significantly higher than the 
extent of apoptosis seen in the 
control, matrine and RGD-LCL 
groups. (A) control group, (B) 
matrine at 0.03125 mg/mL, (C) 
RGD-LCL at 0.625 mg/mL, (D) 
RGD-M-LCL equivalent to these concentration of matrine and RGD-LCL.  Int. J. Med. Sci. 2010, 7 
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Discussion 
Liposomes are well-recognized drug delivery 
vehicles that utilize the fusion of their phospholipid 
bilayer membrane to the cellular plasma membrane to 
enhance the delivery and subsequent therapeutic ac-
tivity of anticancer drugs. However, conventional 
liposomes are rapidly cleared by the reticular endo-
thelial system in vivo. Furthermore, liposomes interact 
with plasma proteins, resulting in poor specific tar-
geting and a short circulation time. An efficient drug 
delivery system is needed that can 1) protect drugs 
from clearance and degradation to keep sufficient 
circulation-action time in vivo, 2) suppress nonspecific 
u p t a k e  b y  n o r m a l  o r  n o n - t a r g e t  t i s s u e s ,  3 )  m e d i a t e  
accumulation of drugs within the target tissues and 
cells (23).  
To achieve these three goals, we first prepared 
LCL modified with PEG to lengthen their circulation 
time in vivo and improve their passive targeting. De-
rivatives of PEG provide a hydrophilic surface for the 
liposomes and reduce their interactions with plasma 
proteins. Furthermore, this addition increased the 
molecules’ steric hindrance, shielding them from be-
ing recognized by the reticular endothelial system 
(24). Compared with normal tissues, tumor tissues 
have characteristics such as an enlarged interspace 
between vascular endothelial cells (about 
400~800nm), increased vascular permeability, and 
reduced lymphatic return, which make liposomes of 
200~400nm accumulate within tumor tissues through 
the EPR effect (25). This accumulation keeps a higher 
concentration of the drug in the tumor than in other 
tissues, and increases its duration of action. Second, 
we modified the surface of the liposomes with the 
RGD motif to further improve their active tumor tar-
geting through the endocytotic mechanism mediated 
by specific ligands.  
In previous studies, PS Reddy et al (14) inserted 
an RGD motif into the knob domain of an adenovirus 
so that a re-target vector used integrin as a cellular 
receptor to dramatically increase the level of trans-
duction of tumor cells. Similarly, Schmieders et al (26) 
constructed nanoparticles loaded with siRNA and 
polyethyleneimine (PEI) that were PEGylated with an 
RGD peptide ligand as a means to target the tumor 
neovasculature expressing integrins, and used them 
to deliver siRNA against vascular endothelial growth 
factor receptor-2 (VEGF-R2). Besides rapid growth, 
tumor tissues also undergo exten-
sive  neovascularization, and depend on the devel-
opment of new blood vessels to supply nutrients and 
growth factors. Integrins are also overexpressed in 
proliferating endothelial cells, while they are not ex-
pressed on quiescent endothelial cells in normal tis-
sues or blood vessels (27), providing a further target 
for the molecules. Based on these studies, we sup-
posed that a drug delivery system modified with RGD 
could not only target tumor cells, but could also target 
the tumor neovasculature through the specific li-
gand-receptor binding, to achieve improved effects.  
In the present study, we prepared LCL with 
HSPC, cholesterol, DSPE-PEG2000 and 
DSPE-PEG-MAL, and modified them with an RGD 
motif. The prepared liposomes were processed by a 
microfluidizer and stored at 4°C. The liposomes were 
stable for at least one month at this temperature, with 
minimal changes in size, although the particle size 
increased when the liposomes were reconstitutes in 
solvent.  
Because matrine is a strongly hydrophilic and 
weakly alkaline drug, the encapsulation efficiency of 
liposomes for loading matrine is very low when pre-
pared by routine methods, such as a thin film disper-
sal method or a reverse evaporation method. To 
achieve better encapsulation, a pH-gradient method 
based on the Henderson-Hasselbalch theory can be 
used. After a desired pH gradient is obtained by ad-
justing the pH values between the liposomes and ex-
ternal medium, the weakly acidic or alkaline drugs 
can cross the phospholipid membrane in molecular 
form following the transmembrane pH gradient, to 
become encapsulated within liposomes in ion form 
(28). We used this method to encapsulate matrine into 
liposomes, and detected their encapsulation efficien-
cy. Our results indicated that the encapsulation effi-
ciency was negatively related to the drug-lipid ratio in 
the range of 0.1~0.4. An encapsulation efficiency of 
83.13% was obtained when the drug-lipid ratio was 
0.1. However, the encapsulation efficiency decreased 
with the duration of storage due to the release of wa-
ter-soluble drugs. Lyophilization of the liposomes 
was thus used to improve their storage stability. Al-
though the size of the liposomes after freeze-drying 
increased from 100nm to 300nm, their encapsulation 
efficiency was still maintained at a high level. Our 
study suggested that for liposomes of water-soluble 
drugs, the pH-gradient mediated active loading me-
thod, and lyophilization of liposomes, might be op-
timal methods for preparation and preservative, re-
spectively.  
In our preliminary validation of the anti-tumor 
effects of RGD-M-LCL in vitro, we observed that the 
molecule strongly inhibited the growth of Bcap-37, 
HT-29 and A375 cells, three cell lines representing 
different tissues expressing integrin receptors. This Int. J. Med. Sci. 2010, 7 
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activity was significantly stronger than that observed 
when cells were treated with free matrine. In order to 
demonstrate that the activity of the molecule was due 
to the complexed matrine, rather than the RGD-LCL, 
we treated Bcap-37 cells with RGD-LCL of different 
concentrations and RGD-M-LCL equivalent to 
RGD-LCL. We observed that high concentrations of 
RGD-LCL alone induced cytotoxicity, but that the 
complex alone had minimal toxicity at lower concen-
trations, indicating that most of the activity is attri-
butable to the complexed matrine. More importantly, 
RGD-M-LCL was much more cytotoxic than matrine 
alone. We presumed that this was because 
RGD-M-LCL could accumulate more matrine within 
the target cells, leading to increased anti-cancer activ-
ity. In addition, RGD-M-LCL also induced more 
apoptosis than the equivalent dose of free matrine or 
RGD-LCL, although the RGD-LCL did also induce 
apoptosis to a lesser extent. We speculated that this 
was because the RGD conjugated to the surface of 
liposomes, just like the exogenous RGD peptide, not 
only had the desired homing effect to target tumor 
cells and deliver anti-tumor drugs, but also had direct 
effects on cell viability and apoptosis (29,30). This will 
need to be confirmed in further studies, and the me-
chanism underlying this effect is unclear.which 
needed further confirmation.  
In conclusion, we have successfully prepared 
RGD-modified long circulating liposome loaded with 
matrine (RGD-M-LCL), and confirmed that 
RGD-M-LCL had much stronger anti-cancer effects 
than free matrine or RGD-LCL alone. This study pro-
vides an effective model drug for subsequent research 
on the pharmacokinetics, in vivo efficacy and target-
ing mechanism of the RGD-LCL drug-loaded system.  
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